|
1
|
Derdau V, Elmore CS, Hartung T, McKillican B, Mejuch T, Rosenbaum C, Wiebe C. The Future of (Radio)-Labeled Compounds in Research and Development within the Life Science Industry. Angew Chem Int Ed Engl 2023; 62:e202306019. [PMID: 37610759 DOI: 10.1002/anie.202306019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Revised: 08/23/2023] [Accepted: 08/23/2023] [Indexed: 08/24/2023]
Abstract
In this review the applications of isotopically labeled compounds are discussed and put into the context of their future impact in the life sciences. Especially discussing their use in the pharma and crop science industries to follow their fate in the environment, in vivo or in complex matrices to understand the potential harm of new chemical structures and to increase the safety of human society.
Collapse
Affiliation(s)
- Volker Derdau
- Sanofi-Aventis Deutschland GmbH, Research & Development, Integrated Drug Discovery, Isotope Chemistry, Industriepark Höchst, G876, 65926, Frankfurt am Main, Germany
| | - Charles S Elmore
- Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Mölndal, Sweden
| | - Thomas Hartung
- Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Bruce McKillican
- Syngenta Crop Protection, LLC, North America Product Safety (retired), USA
| | - Tom Mejuch
- BASF SE, Agricultural Solutions, Ludwigshafen, Germany
| | | | | |
Collapse
|
|
2
|
Perkins JJ, McQuade P, Bungard CJ, Diamond TL, Gantert LT, Gotter AL, Hanney B, Hills ID, Hurzy DM, Joshi A, Kern JT, Schlegel KAS, Manikowski JJ, Meng Z, O’Brien JA, Roecker AJ, Smith SM, Uslaner JM, Hostetler E, Meissner RS. Discovery of [ 11C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR 2 Negative Allosteric Modulators. ACS Med Chem Lett 2023; 14:986-992. [PMID: 37465306 PMCID: PMC10351059 DOI: 10.1021/acsmedchemlett.3c00175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 06/09/2023] [Indexed: 07/20/2023] Open
Abstract
Modification of potent, selective metabotropic glutamate receptor 2 negative allosteric modulator (mGluR2 NAM) led to a series of analogues with excellent binding affinity, lipophilicity, and suitable physicochemical properties for a PET tracer with convenient chemical handles for incorporation of a 11C or 18F radiolabel. [11C]MK-8056 was synthesized and evaluated in vivo and demonstrated appropriate affinity, selectivity, and physicochemical properties to be used as a positron emission tomography tracer for mGluR2.
Collapse
Affiliation(s)
- James J. Perkins
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Paul McQuade
- Translational
Imaging, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Christopher J. Bungard
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Tracy L. Diamond
- Pharmacology, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Liza T. Gantert
- Translational
Imaging, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Anthony L. Gotter
- Neuroscience
Biology Discovery, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Barbara Hanney
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Ivory D. Hills
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Danielle M. Hurzy
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Aniket Joshi
- Translational
Imaging, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Jonathan T. Kern
- Neuroscience
Biology Discovery, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Kelly-Ann S. Schlegel
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Jesse J. Manikowski
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Zhaoyang Meng
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Julie A. O’Brien
- Pharmacology, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Anthony J. Roecker
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Sean M. Smith
- Neuroscience
Biology Discovery, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Jason M. Uslaner
- Neuroscience
Biology Discovery, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Eric Hostetler
- Translational
Imaging, Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| | - Robert S. Meissner
- Departments
of Discovery Chemistry, Merck & Co.,
Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, USA
| |
Collapse
|
|
3
|
Auberson YP, Lièvre A, Desrayaud S, Briard E. A practical approach to the optimization of positron emission tomography (PET) imaging agents for the central nervous system. J Labelled Comp Radiopharm 2022; 65:343-350. [PMID: 36148533 DOI: 10.1002/jlcr.4004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 09/20/2022] [Accepted: 09/21/2022] [Indexed: 11/08/2022]
Abstract
The discovery of novel imaging agents for positron emission tomography (PET) relies on medicinal chemistry best practices, including a good understanding of molecular and pharmacological properties required for the acquisition of relevant, high-quality images. This short note reviews the characteristics of a series of clinically successful imaging agents, providing guidance for the optimization of such molecular tools. PET imaging plays an important role in staging disease and in helping clinical dose selection, which is critical for the efficient development of drug candidates.
Collapse
Affiliation(s)
- Yves P Auberson
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Akané Lièvre
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | | |
Collapse
|
|
4
|
Heurling K, Ashton NJ, Leuzy A, Zimmer ER, Blennow K, Zetterberg H, Eriksson J, Lubberink M, Schöll M. Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Mol Cell Neurosci 2019; 97:34-42. [PMID: 30796959 DOI: 10.1016/j.mcn.2019.02.001] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 02/05/2019] [Accepted: 02/07/2019] [Indexed: 01/12/2023] Open
Abstract
Measuring synaptic density in vivo using positron emission tomography (PET) imaging-based biomarkers targeting the synaptic vesicle protein 2A (SV2A) has received much attention recently due to its potential research and clinical applications in synaptopathies, including neurodegenerative and psychiatric diseases. Fluid-based biomarkers in proteinopathies have previously been suggested to provide information on pathology and disease status that is complementary to PET-based measures, and the same can be hypothesized with respect to SV2A. This review provides an overview of the current state of SV2A PET imaging as a biomarker of synaptic density, the potential role of fluid-based biomarkers for SV2A, and related future perspectives.
Collapse
Affiliation(s)
- Kerstin Heurling
- Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden.
| | - Nicholas J Ashton
- Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South, Maudsley NHS Foundation, London, UK
| | - Antoine Leuzy
- Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Memory Research Unit, Lund University, Sweden
| | - Eduardo R Zimmer
- Department of Pharmacology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Graduate Program in Biological Sciences: Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK
| | - Jonas Eriksson
- Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; PET Centre, Uppsala University Hospital, Uppsala, Sweden
| | - Mark Lubberink
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Medical Physics, Uppsala University Hospital, Uppsala, Sweden
| | - Michael Schöll
- Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden; Clinical Memory Research Unit, Lund University, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
| |
Collapse
|